SGX301 has previously been granted both orphan drug and fast track designations from the US Food and Drug Administration (FDA) for the first-line treatment of CTCL, a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
Ceptaris Therapeutics, Inc., a privately held specialty pharmaceutical company, announced on June 5, 2012 that it has raised $10 million in Series D-1 financing for the operational expenses of producing mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides. Ceptaris has also received a Complete Response Letter from the FDA regarding the New Drug Application (NDA) for the gel.
Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today it has changed its name to Ceptaris Therapeutics, Inc., effective immediately. The new name is intended to reflect the recent changes in management and the Company’s ongoing transformation into a commercial organization. Ceptaris Therapeutics’ lead drug candidate, mechlorethamine gel, is currently undergoing review by the U.S. Food and Drug Administration (FDA) for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of cutaneous T-cell Lymphoma (CTCL).